Drugs / STC-15
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial · 1 met primary | ||||||
| Phase 1 | NCT05584111 | Nov 2022 → Aug 2024 | cancer | STORM Therapeutics LTD | Completed | Met primary |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06975293 | May 2025 → Dec 2027 expected | dedifferentiated liposarcoma, leiomyosarcoma | STORM Therapeutics LTD | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 7
| Date | Issuer | Release |
|---|---|---|
| 2026-05-22 | STORM Therapeutics LTD | Results STORM Therapeutics to Present Promising Phase 1 Sarcoma Data Demonstrating Activity of First‑in‑Class METTL3 Inhibitor STC‑15 at ASCO 2026 stormtherapeutics.com ↗
Encouraging clinical activity in the sarcoma subset includes: Evidence of clinical activity consistent with a differentiation‑driven mechanism of action, with disease control observed across multiple sarcoma subtypes |
| 2024-11-11 | STORM Therapeutics LTD | Results STORM Therapeutics Presents New Clinical Data on its First-in-Class METTL3 Inhibitor STC-15 at SITC 2024 stormtherapeutics.com ↗
Tumor regressions were achieved at all dose levels, 60 mg - 200 mg three times a week (TIW), with three sustained Partial Responses (PRs) at 60 mg, 100 mg, and 200 mg TIW in multiple tumor types |
| 2024-10-09 | STORM Therapeutics LTD | Results STORM Therapeutics to Present Phase 1 Data on its First-in-Class Lead Product STC-15 at EORTC-NCI-AACR Symposium stormtherapeutics.com ↗
The data generated show encouraging signs of clinical activity, promising biomarker data and significant reductions in methylated polyA-RNA in blood samples from all cohorts, demonstrating METTL3 target engagement and rapid PD effect. |
| 2024-06-03 | STORM Therapeutics LTD | Results STORM Therapeutics Presented Interim Phase 1 Clinical Data on its METTL3 RNA Methyltransferase Inhibitor STC-15 at ASCO 2024 stormtherapeutics.com ↗
STC-15 was well tolerated and clinical activity was observed across the pharmacologically active dose range in advanced cancer patients |
| 2023-10-17 | STORM Therapeutics LTD | Results STORM Therapeutics Presented Novel Pre-Clinical Data on STC-15 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics stormtherapeutics.com ↗
STC-15 synergises with radiation therapy in vivo |
| 2023-08-08 | STORM Therapeutics LTD | Results STORM Therapeutics publishes data in Cancer Discovery showing induction of anti-tumour immunity by METTL3 inhibition stormtherapeutics.com ↗
Using pre-clinical cancer models, the study shows that pharmacological inhibition of METTL3 induces double-stranded RNA formation and a profound cell-intrinsic interferon response that potentiates T-cell killing of cancer cells. |
| 2023-01-25 | STORM Therapeutics LTD | Results STORM Therapeutics Presents STC-15 Preclinical Data Supporting Treatment of Patients with AML at the AACR Acute Myeloid Leukemia and Myelodysplastic Syndrome Conference stormtherapeutics.com ↗
Data demonstrates that STC-15, an oral METTL3 inhibitor, exhibits efficacy as a single agent and in combination with venetoclax using patient-derived tumor models |
All press releases naming this drug 10 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | STC-15 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06975293 ↗ |
| Action | Inhibit | “STC-15, a METTL-3 Inhibitor” NCT05584111 ↗ |
| Route | Oral | “STC-15 oral capsules various dosing regimen in 3-week cycles” NCT05584111 ↗ |
| Target | METTL3 | “STC-15, a METTL-3 Inhibitor” NCT05584111 ↗ |